Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuren Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$2.38 billion
P/E Ratio
15.70
Dividend Yield
0.00%
Shares Outstanding
129.95 million
Earnings per share
1.201
Dividend per share
N/A
Year To Date Return
-24.51%
Earnings Yield
6.37%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuren Pharmaceuticals Ltd (ASX: NEU)
Latest News
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
These were the best performers on the ASX 200 in November
Healthcare Shares
Buy this ASX 200 stock for big returns after 'impressive launch'
Share Market News
5 things to watch on the ASX 200 on Monday
Share Market News
Here's how the ASX 200 market sectors stacked up this week
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Why Block, Core Lithium, Neuren, and Tietto shares are charging higher
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Frequently Asked Questions
-
No, Neuren Pharmaceuticals does not pay dividends at this time.
-
Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.
NEU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.
Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi.
Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.
NEU Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 26 Apr 2024 | $18.65 | $-0.20 | -1.06% | 566,651 | $18.85 | $18.92 | $18.35 |
| 24 Apr 2024 | $18.85 | $-0.45 | -2.33% | 266,295 | $19.30 | $19.52 | $18.82 |
| 23 Apr 2024 | $19.30 | $0.02 | 0.10% | 149,881 | $19.60 | $19.86 | $19.19 |
| 22 Apr 2024 | $19.28 | $0.36 | 1.90% | 234,347 | $19.29 | $19.45 | $19.07 |
| 19 Apr 2024 | $18.92 | $-0.75 | -3.81% | 449,254 | $19.28 | $19.42 | $18.62 |
| 18 Apr 2024 | $19.67 | $0.16 | 0.82% | 260,297 | $19.51 | $19.90 | $19.30 |
| 17 Apr 2024 | $19.51 | $0.06 | 0.31% | 245,692 | $19.45 | $19.62 | $18.88 |
| 16 Apr 2024 | $19.45 | $-0.95 | -4.66% | 501,181 | $20.19 | $20.28 | $19.38 |
| 15 Apr 2024 | $20.40 | $-0.36 | -1.73% | 318,137 | $20.56 | $20.66 | $20.25 |
| 12 Apr 2024 | $20.76 | $0.04 | 0.19% | 201,147 | $20.60 | $20.90 | $20.42 |
| 11 Apr 2024 | $20.72 | $-0.22 | -1.05% | 157,887 | $20.49 | $20.84 | $20.48 |
| 10 Apr 2024 | $20.94 | $0.45 | 2.20% | 325,406 | $20.60 | $21.44 | $20.50 |
| 09 Apr 2024 | $20.49 | $-0.31 | -1.49% | 176,746 | $20.66 | $20.95 | $20.26 |
| 08 Apr 2024 | $20.80 | $0.03 | 0.14% | 284,006 | $20.90 | $21.38 | $20.68 |
| 05 Apr 2024 | $20.77 | $-0.03 | -0.14% | 312,442 | $20.53 | $20.92 | $20.37 |
| 04 Apr 2024 | $20.80 | $0.40 | 1.96% | 196,887 | $20.72 | $20.94 | $20.40 |
| 03 Apr 2024 | $20.40 | $-1.11 | -5.16% | 300,557 | $21.09 | $21.49 | $20.40 |
| 02 Apr 2024 | $21.51 | $0.29 | 1.37% | 281,378 | $21.23 | $21.75 | $21.00 |
| 28 Mar 2024 | $21.22 | $0.45 | 2.17% | 374,911 | $20.76 | $21.43 | $20.70 |
| 27 Mar 2024 | $20.77 | $0.53 | 2.62% | 304,897 | $20.13 | $20.77 | $20.13 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 13 Sep 2023 | Joseph(Joe) Basile | Buy | 5,000 | $59,950 |
On-market trade.
|
| 14 Jun 2023 | Trevor Scott | Sell | 1,175,000 | $15,275,000 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Trevor D Scott | Non-Executive Director | Mar 2002 |
Trevor joined the Neuren Board in 2002. He is the founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. He is an experienced advisor to companies across a variety of industries. Trevor serves on numerous corporate boards and is chairman of several.
|
| Ms Dianne Margaret Angus | Non-Executive Director | Jul 2018 |
Dianne joined the Neuren Board in 2018. She has worked as a senior executive and non-executive director within
the biotechnology, biopharmaceutical and agritech industries for over twenty-five years. She has created numerous global industry partnerships which include Prana Biotechnology, Gerolymatos International, Florigene, Suntory & Monsanto to yield novel and competitive medical, pharmaceutical and agricultural products. Dianne has successfully forged strong partnerships with key medical opinion leaders to create innovative clinical research programs and driven the development path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA and European regulators. With over fifteen years experience in an ASX and NASDAQ listed company, she has expertise in business development, capital raising, investor relations, regulatory affairs and intellectual property, together with corporate governance and compliance capabilities. Dianne holds a Masters degree in biotechnology and is a registered patent attorney. |
| Mr Jonathan (Jon) Charles Pilcher | Chief Executive OfficerManaging Director | Aug 2013 |
Jon joined Neuren in 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren s R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acruxs IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK. He is a non executive director of BTC Health Limited (ASX: BTC).
|
| Dr Jenny Lee Harry | Non-Executive Director | Jul 2018 |
Jenny joined the Neuren Board in 2018. She has 20 years experience in executive management of companies in the
biotechnology and biopharmaceutical industry. Jenny is an accomplished CEO and Managing Director with experience in growing companies from start up to commercialisation. She has served on Boards of a number of listed and unlisted companies and is currently a Non Executive Director of Aeris Environmental Limited (ASX:AEI) and on the Boards IP sub-committee of the Childrens Medical Research Institute. Jenny is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. |
| Mr Patrick Davies | Non-Executive DirectorNon-Executive Chairman | Jul 2018 |
Patrick joined the Neuren Board in 2018. He has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed successfully in senior roles across many industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
|
| Mr Joseph(Joe) Basile | Non-Executive Director | Mar 2023 |
Mr Basile has held a number of executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia. Joe has experience in corporate mergers and acquisitions, capital management and overseeing expansion activities .
|
| Ms Lauren Frazer | Chief Financial OfficerCompany Secretary | Aug 2020 |
-
|
| Lauren Frazer | Chief Financial OfficerCompany Secretary |
-
|
|
| LIZA SQUIRES, M.D. | Chief Medical Officer |
-
|
|
| LARRY GLASS | Chief Science Officer |
-
|
|
| VIRGINIE DUREZ | Senior Director Product Development & Project Management |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| NATIONAL NOMINEES LIMITED | 11,810,223 | 9.35% |
| Citicorp Nominees Pty Limited | 10,759,990 | 8.52% |
| HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED | 9,174,182 | 7.27% |
| J P Morgan Nominees Australia Pty Limited | 8,875,428 | 7.03% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 6,639,176 | 5.26% |
| Cameron Richard Pty Ltd | 4,206,313 | 3.33% |
| BNP Paribas Noms Pty Ltd | 2,710,864 | 2.15% |
| Stuart Andrew Pty Ltd | 2,460,000 | 1.95% |
| Essex Castle Limited | 2,367,144 | 1.87% |
| Smithley Super Pty Ltd | 2,010,000 | 1.59% |
| Linwierik Super Pty Ltd | 1,885,000 | 1.49% |
| Sharesies Nominee Limited | 1,385,966 | 1.10% |
| Mxb Investments Llc | 1,330,000 | 1.05% |
| Dr Trevor Scott | 1,000,000 | 0.79% |
| First Colbyco Pty Ltd | 790,000 | 0.63% |
| Mjhft Pty Ltd | 750,000 | 0.59% |
| Dr Robin Lance Congreve | 671,637 | 0.53% |
| Hobson Wealth Custodians Ltd | 589,337 | 0.47% |
| Emancipayte Pty Ltd | 476,607 | 0.38% |
| Bnp Paribas Nominees Pty Ltd Acf Clearstream | 465,450 | 0.37% |
